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Summary
The protozoan Trypanosoma brucei has a functional
pteridine reductase (TbPTR1), an NADPH-dependent
short-chain reductase that participates in the salvage
of pterins, which are essential for parasite growth.
PTR1 displays broad-spectrum activity with pterins
andfolates,providesametabolicbypassforinhibition
of the trypanosomatid dihydrofolate reductase and
therefore compromises the use of antifolates for treat-
ment of trypanosomiasis. Catalytic properties of
recombinant TbPTR1 and inhibition by the archetypal
antifolate methotrexate have been characterized and
thecrystalstructureoftheternarycomplexwithcofac-
tor NADP+ and the inhibitor determined at 2.2 Å reso-
lution. This enzyme shares 50% amino acid sequence
identity with Leishmania major PTR1 (LmPTR1) and
comparisons show that the architecture of the cofac-
tor binding site, and the catalytic centre are highly
conserved, as are most interactions with the inhibitor.
However, speciﬁc amino acid differences, in particular
the placement of Trp221 at the side of the active site,
and adjustment of the b6-a6 loop and a6 helix at one
side of the substrate-binding cleft signiﬁcantly reduce
the size of the substrate binding site of TbPTR1 and
alter the chemical properties compared with LmPTR1.
A reactive Cys168, within the active site cleft, in con-
junction with the C-terminus carboxyl group and
His267 of a partner subunit forms a triad similar to the
catalytic component of cysteine proteases. TbPTR1
therefore offers novel structural features to exploit in
the search for inhibitors of therapeutic value against
African trypanosomiasis.
Introduction
Trypanosomatid protozoans are auxotrophic for folate and
other pterins (Kidder and Dutta, 1958; Beck and Ullman,
1990)andhaveevolvedasophisticatedpathwayforacqui-
sition and salvage of pteridines from their hosts by relying
on a bifunctional dihydrofolate reductase (DHFR; EC
1.5.1.3) – thymidylate synthase (TS; EC 2.1.1.45) together
with pteridine reductase (PTR1; EC 1.5.1.33) to carry out
reductions of these essential nutrients (Nareet al., 1997a).
The metabolic pathway that generates reduced folate
cofactors is a successful target for the treatment of bacte-
rial infections and some parasitic diseases, notably
malaria. This is mainly achieved by inhibition of DHFR
(Gilman et al., 1990; Blakley, 1995; Kompis et al., 2005)
and in theory antifolates should provide useful drugs for
diseases that result from infection with trypanosomatids.
These include diseases such asAfrican sleeping sickness
caused by Trypanosoma brucei gambiense or Trypano-
somabruceirhodesiense.However,theclassicalinhibitors
of folate biosynthesis are ineffective against Leishmania
and Trypanosoma, with resistance mediated through
several mechanisms including the ampliﬁcation of PTR1
(Hardy et al., 1997; Nare et al., 1997a).
PTR1 is a short-chain dehydrogenase/reductase (SDR)
able to catalyse the NADPH-dependent two-stage reduc-
tion of oxidized pterins to the active tetrahydro-forms
(Bello et al., 1994; Nare et al., 1997b; Luba et al., 1998).
The enzyme exhibits broad reductase activity, capable of
reducing unconjugated (e.g. biopterin) and conjugated
(folate) pterins from either the oxidized or dihydro-state
(Fig. 1). PTR1 is the only enzyme known to reduce biop-
terin in Leishmania and knockout of the gene indicates
that this activity is essential for parasite growth in vitro
(Bello et al., 1994). The biochemical activities of Leishma-
nia major PTR1 (LmPTR1) overlap those of DHFR but as
PTR1 is less susceptible to inhibition by antifolates it
provides a metabolic bypass to alleviate DHFR inhibition
(Nare et al., 1997a). The Trypanosoma cruzi PTR1 homo-
Accepted 17 July, 2006. *For correspondence. E-mail w.n.hunter@
dundee.ac.uk; Tel. (+44) 1382 385745; Fax (+44) 1382 345764.
†Present address: Department of Chemistry, University of Glasgow,
Glasgow G12 8QQ, UK.
Re-use of this article is permitted in accordance with the Creative
Commons Deed, Attribution 2.5, which does not permit commercial
exploitation.
Molecular Microbiology (2006) 61(6), 1457–1468 doi:10.1111/j.1365-2958.2006.05332.x
First published online 10 August 2006
© 2006 The Authors
Journal compilation © 2006 Blackwell Publishing Ltdlogue (TcPTR1) when overexpressed in vitro also leads to
antifolate resistance (Robello et al., 1997). Gene deletion
studies in T. brucei have demonstrated that DHFR-TS is
essential for growth and null mutants are only able to grow
in media supplemented with thymidine. There is also
increased resistance to antifolates (N. Sienkiewicz and
A.H. Fairlamb, unpubl. data).
The drugs used for treatment of the trypanosomiases
are unsatisfactory due to poor efficacy and high toxicity in
addition to practical difficulties of administration (Fairlamb,
2003). In principle, the dual inhibition of PTR1 and DHFR
activity of trypanosomatids should provide a new thera-
peutic approach therefore a comprehensive understand-
ing of the structure–activity relationships of the drug
targets is required to support the search for such an
urgently required therapy. The structure of L. major
DHFR-TS is known (Knighton et al., 1994) and there is an
extensive literature on and medical experience on the
targeting of DHFR (Gilman et al., 1990; Blakley, 1995;
Kompis et al., 2005).
The kinetics and stereochemical course of the red-
uctions catalysed by LmPTR1 have been studied together
with analysis of a library of inhibitors (Hardy et al., 1997;
Luba et al., 1998). We have reported crystal structures
of LmPTR1 in ternary complexes with cofactor, sub-
strates and products [biopterin, 2-amino-7,8-dihydro-6-
(1,2-dihydroxypropyl)pteridin-4(3H)-one (DHB), 2-amino-
5,6,7,8-tetrahydro-6-(1,2-dihydroxypropyl)pteridin-4(3H)-
one (THB)], and with inhibitors including methotrexate
(MTX, 4-amino-N10-methyl-pteroylglutamic acid; Fig. 2A;
Gourley et al., 2001; McLuskey et al., 2004; Schüttelkopf
et al., 2005). Other laboratories have reported structures
of PTR1 from L. tarentolae (Zhao et al., 2003) and PTR2,
an isoform from T. cruzi (Schormann et al., 2005).
We set out to conﬁrm the assignment of a functional
PTR1 in T. brucei (TbPTR1) and now report on the reac-
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Fig. 1. The two-stage reduction of biopterin
[2-amino-6-(1,2-dihydroxypropyl) pteridin-4(3H)-one] to
7,8-dihydrobiopterin [DHB,
2-amino-7,8-dihydro-6-(1,2-dihydroxypropyl)pteridin-4(3H)-one] then
to 5,6,7,8-tetrahydrobiopterin [THB,
2-amino-5,6,7,8-tetrahydro-6-(1,2-dihydroxypropyl)pteridin-4(3H)-one]
catalysed by PTR1. Each stage requires one reducing equivalent
provided by the cofactor NADPH and the C atoms (C7 and C6) that
accept the hydride are marked with an asterisk (*). This ﬁgure and
Fig. 2A were prepared using ChemDraw (CambridgeSoft, USA).
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Fig. 2. A. The chemical structure of methotrexate (MTX).
B. The difference density omit map (chicken wire) for MTX in active
site A, calculated with (Fo -F c), ac coefficients and contoured at the
3 s level. Fo represents the observed structure factors, Fc the
calculated structure factors and ac the calculated phases. The
atomic co-ordinates depicted in this ﬁgure did not contribute to Fc
or ac.
MTX in this and subsequent ﬁgures is depicted in stick-mode with
atomic positions coloured C black, N blue, O red. Figures showing
molecular structures were prepared using PyMOL (DeLano, 2002).
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derived from other trypanosomatid parasites. Accurate
molecular details are critical to support a structure-based
approach to inhibitor design and we have determined the
crystal structure of the ternary complex with NADP+ and
MTX. Comparisons of PTR1 from different species allow
us to investigate the feasibility of developing a broad-
spectrum PTR1 inhibitor or to see whether the enzyme
from a speciﬁc trypanosomatid species might provide dis-
tinct and new opportunities for inhibitor design.
Results and discussion
Enzyme activity: T. brucei possesses a functional PTR1
A candidate gene for TbPTR1 was cloned, the recombi-
nant protein produced in Escherichia coli puriﬁed in high
yield, of greater than 30 mg of enzyme from each litre of
culture, and proven to be enzymatically active. The
optimum pH for reduction of biopterin and DHB by
TbPTR1 is 3.7 with speciﬁc activities of 2.0 and
2.3 mmol min-1 mg-1 protein respectively. TbPTR1 dis-
plays a uniformly low level of activity with respect to reduc-
tion of folate and dihydrofolate (DHF), in each case with
maximum speciﬁc activity about 0.1 mmol min-1 mg-1.
For reasons that are not understood, PTR1 from differ-
ent species display different activities. TbPTR1 is equally
active with biopterin and DHB as substrates but relatively
insensitive to folate and DHF. TcPTR1 is more active with
biopterin and folate than with DHB or DHF (Robello et al.,
1997) while the isoform TcPTR2 is only active against
reduced pterins, DHB and DHF (Schormann et al., 2005).
TbPTR1 is more active than LmPTR1 with respect to
reduction of pterins and the enzymes have different pH
optima. For LmPTR1 the pH optimum is at 4.7 compared
with 3.7 for TbPTR1. TbPTR1 displays substrate inhibition
with DHB as variable substrate as reported for LmPTR1
(Nare et al., 1997b). The apparent kinetic constants for
DHB are similar: Km = 10.9 (2.4) versus 7.6 mM and Ki
S
= 3.8 (0.7) versus 14.5 mM for TbPTR1 and LmPTR1
respectively. However, Vmax is approximately 10-fold
higher for the T. brucei enzyme (9.1  1 . 2Um g -1) com-
pared with LmPTR1 (0.87 U mg-1) yielding kcat = 4.7 s-1
and kcat/Km = 4.3 ¥ 105 M-1 s-1 for TbPTR1 and kcat =
0.44 s-1 and kcat/Km = 5.8 ¥ 104 M-1 s-1 for LmPTR1. In
contrast to LmPTR1, TbPTR1 appears to be at least four-
fold less efficient in reducing folate and DHF over the pH
range 4–8. MTX, a molecule of similar shape and mass to
folate (Fig. 2), inhibits TbPTR1 less well than it does to
LmPTR1. The Ki for MTX inhibition of LmPTR1 is reported
as 58 (15) nM (Nare et al., 1997b) and in our hands 39
(19) nM, which is a good agreement. The Ki is 152
(16) nM with respect to TbPTR1. The slower catalysis of
folates and weaker inhibition displayed by MTX against
TbPTR1 may be due to the presence of a less ﬂexible and
restricted binding pocket in that enzyme compared with
LmPTR1 (see active site description below).
Comments on the crystallographic model
The structure of TbPTR1 has been determined to 2.2 Å
resolution and statistics are presented in Table 1. The
stereochemistry of the model is acceptable as judged by
standard criteria and the ﬁt of the model to the electron
density is good. As an example, Fig. 2B shows the omit
difference density map associated with a MTX molecule.
The asymmetric unit consists of a homotetramer, which
represents the functional unit, and overlays of the 251
residues common to each of the four subunits show a root
mean square deviation (r.m.s.d.) range in Ca positions of
0.19–0.31 Å (mean 0.25 Å). Visual inspection conﬁrms
this high degree of structural conservation. This consis-
tency, without the use of non-crystallographic symmetry
(NCS) restraints, indicates that it is only necessary to
detail one subunit and one enzyme active site, arbitrarily
chosen as subunit A.
Table 1. Data collection, reﬁnement and model geometry statistics.
Resolution range 20–2.2 Å
No. of measurements/unique reﬂections 139 124/50 048
Redundancy/completeness (%) 2.8/99.2 (93.1)
a
I/s(I) 12.4 (3.5)
a
Rmerge (%)
b 4.6 (15.0)
a
Wilson B (Å
2) 24.2
Protein residues (total) 1024
In subunits A–D 253, 254, 260, 257
Additional groups
Solvent/NADP
+/MTX/Ni
2+/acetate/
cacodylate
801/4/4/2/2/8
Rwork (%)
c/No. of reﬂections 15.35/47 369
Rfree (%)
d/No. of reﬂections 22.3/2534
Average isotropic thermal parameters (Å
2)
Subunits A–D 23.1, 22.6, 23.9, 24.8
NADP
+ 18.7, 17.8, 18.0, 18.9
MTX pteridine 19.8, 16.0, 17.0, 16.8
MTX pABA 23.6, 21.6, 23.8, 26.1
MTX g-Glu 33.0, 31.5, 38.6, 38.7
Solvents/dimethyl arsinoyl moiety
r.m.s.d. bond lengths (Å)/angles (°)
33.2
0.013/1.402
DPI
e 0.208
Ramachandran analysis (%)
Favoured and allowed regions 99.9
Generously allowed regions 0.1 (Arg14 in each
subunit)
a. Values in parentheses refer to the highest resolution bin approxi-
mately 2.3–2.2 Å.
b. Rmerge =S hSi|I(h,i)–I(h)|/ShSi I(h,i), where I(h,i) is the intensity
of the ith measurement of reﬂection h and I(h) is the mean value
of I(h,i) for all i measurements.
c. Rwork =S hkl||Fo| - |Fc||/S|Fo|, where Fo is the observed structure-
factor amplitude and Fc the structure-factor amplitude calculated from
the model.
d. Rfree is the same as Rwork except only calculated using a subset,
5%, of the data that are not included in any least squares reﬁnement
calculations.
e. DPI, diffraction-component precision index (Cruickshank, 1999).
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The TbPTR1 subunit forms a single a/b-domain con-
structed around a seven-stranded parallel b-sheet sand-
wiched between two sets of a-helices (Fig. 3A). This
structure is typical of the SDR superfamily (Duax et al.,
2003; Oppermann et al., 2003). The functional tetramer
displays point group 222 (Fig. 3B), with two active sites,
separated by approximately 25 Å, on each side of the
assembly. Subunit A participates in extensive interactions
with subunits B and C. The interface formed with subunit
D covers a much smaller area and involves the
C-terminus of each subunit placed between the b5-a5
loop and C-terminus of the partner subunit. This interface
places a basic residue, Arg287 or His267 in LmPTR1 and
TbPTR1, respectively, of one subunit near to the catalytic
centre of the partner subunit. This will be discussed later.
A structure-based sequence alignment of TbPTR1 and
LmPTR1, the sequences share 51% identity, is shown in
Fig. 4A. The TbPTR1 topology is closely related to
LmPTR1; an overlay of one monomer of TbPTR1 onto
one subunit of LmPTR1 matches 244 residues with an
r.m.s.d. of 0.71 Å (Fig. 4B). The TbPTR1 sequence is
shorter than LmPTR1 due to two deletions and a trunca-
tion at the N-terminus. In TbPTR1 a short b3-a3 loop is
well ordered whereas in LmPTR1, the loop is extended by
13 residues and generally disordered (Schüttelkopf et al.,
2005). A second, smaller deletion of four residues occurs
at the C-terminal segment of the loop linking b4 and a4i n
TbPTR1. This loop is also surface-exposed and disor-
dered in both TbPTR1 and LmPTR1.
The sequence and structure alignments indicate a
strong conservation of sequence in elements of second-
ary structure, in sections of the protein involved in cofactor
binding and the catalytic centre. A notable exception con-
cerns the b6-a6 loop and a6 itself, which are placed
adjacent to the catalytic centre, and will be discussed
below.
The cofactor binding site and catalytic centre
The PTR1 active site is an L-shaped depression nearly
30 Å in length, 22 Å wide and 15 Å deep, formed by the
C-terminal ends of the b-sheet (Fig. 3A), where the cofac-
tor binds in an extended conformation. The catalytic
centre is created by residues from the C-terminal section
of b4 and a5, the two loops between b5-a5 and b6-a6
together with the nicotinamide. Figure 5 shows the
cofactor-binding cleft, with selected residues and details
of nicotinamide binding depicted in Fig. 6. The pattern of
hydrogen bonds formed by SDR family members and
cofactors is, in general, well conserved (Duax et al., 2003)
and such interactions are listed in Table 2.
The adenine moiety is placed in a well-deﬁned cleft
formed by contributions from residues in b1, b2, b3, b4
A
B
Fig. 3. A. Ribbon diagram of the TbPTR1 subunit showing the fold
and position of MTX and cofactor. Helices are coloured cyan and
labelled a or h (310), b-strands are purple and numbered. Cofactor
bonds are drawn as sticks coloured according to atom type; C
yellow, N blue, O red, P orange.
B. Surface representation of the functional tetramer with individual
subunits coloured red, blue, grey and yellow. The cofactor adenine
and MTX g-Glu moieties associated with subunits A and D are
depicted as grey sticks. The view is parallel to a twofold axis of
NCS. His267′ is labelled to identify the incursion of the C-terminus
of one subunit into the active site cleft of an adjacent subunit.
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by three side-chains, Leu63, Ala94 and Thr126 (not
shown), and the aromatic side-chain of His35. Four hydro-
gen bond associations involve the adenine 2′ phosphate
and likely contribute signiﬁcantly to cofactor binding. In
general, two basic residues, an arginine and lysine pair,
bind this phosphate and are recognized as a principal
factor in discrimination for NADPH utilization over NADH
A
B
Fig. 4. A. The primary and secondary structure for TbPTR1 together with the aligned sequence of LmPTR1. Residues shown in white on a
red background are strictly conserved; conservative substitutions are shown in red on a white background. This panel was prepared using
ESPript (Gouet et al., 1999).
B .AC a trace showing the overlap of a subunit of TbPTR1 (black) and LmPTR1 (red). The view is similar to that used in Fig. 3A.
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in TbPTR1, with speciﬁcity provided by a phosphate-
binding pocket formed mainly by the turn between b2 and
a2, the use of main-chain amide groups, contributed from
His35, Asn36, Ser37 and the side-chain hydroxyl of
Ser37. The corresponding residues in LmPTR1 are His38,
Arg39 and Ser40. Hydrogen-bonding interactions with the
adenine component of the cofactor are highly conserved
between TbPTR1 and LmPTR1 with one exception. In
LmPTR1, the adenine N6 amino group donates a hydro-
gen bond to the side-chain carboxylate group of Asp142.
This residue type is conserved in TbPTR1, Glu122, but
the side-chain adopts a different orientation to interact
with the nearby Lys114 thereby removing a hydrogen
bond with the adenine N6 (Fig. 5).
Residues contributed from b1, b4, b5 and the b6-a6
loop create the nicotinamide binding site with the pyridine
nucleotide placed over Ile15 (not shown), Pro204 and
Ser207, and stacked under the MTX pteridine. The pyri-
dine adopts a syn conformation with respect to the ribose
and an intramolecular hydrogen bond is formed between
N7 and the b-phosphate (Fig. 6).
Kinetic studies suggest an ordered ternary complex
mechanism for PTR1, with NADPH binding ﬁrst and
NADP+ dissociating after the reduced pteridine product
vacates the active site (Luba et al., 1998). Crystallo-
graphic analyses of ternary complexes of LmPTR1 with
the substrates and products, biopterin, DHB and THB,
show the pterin ligands in a single orientation participating
in virtually identical interactions with the enzyme and
cofactor (Schüttelkopf et al., 2005). These structures
deﬁne a sequential two-step reduction mechanism
(Fig. 1) and the roles played by three residues, Asp181,
Tyr194 and Lys198 in LmPTR1, which in the ﬁrst catalytic
step resembles that proposed for other SDR family
members. These residues are conserved in TbPTR1
(Asp161, Tyr174 and Lys178; Fig. 6) and serve to position
the nicotinamide of the cofactor for hydride transfer
(Lys178), acquire a proton from solvent (Asp161) and
pass this proton on to the substrate (Tyr174). The second
reduction step, which occurs on the opposite side of the
pterin, is similar to that postulated for DHFR. Nicotinamide
again provides a hydride and activated water supplies the
proton (Gourley et al., 2001).
Hydrogen-bonding interactions involving the Asp–Lys–
Tyr triad and neighbouring residues (Fig. 6) position the
nicotinamide, create the PTR1 catalytic centre and
directly inﬂuence the enzyme’s reactivity. Lys178 partici-
pates in four hydrogen bonds with Asn127, Leu159 and
both hydroxyl groups of the nicotinamide ribose. The side-
chain of Asp161 forms hydrogen-bonding interactions
with Tyr174 on one side and Met163 amide on the other.
Asp161, a key catalytic residue, by association with
Tyr174 facilitates protonation of substrate in the ﬁrst stage
of the enzyme mechanism. The decrease in enzyme
activity as pH is raised likely corresponds to deprotonation
of Asp161. The cofactor forms two hydrogen bonds with
Fig. 5. The active site of TbPTR1. The enzyme surface is shown
as a transparent van der Waals surface coloured C grey, N blue, O
red, S, orange. The cofactor, MTX and selected amino acids are
depicted in stick mode.
Fig. 6. The nicotinamide binding site and selected hydrogen
bonds. Conventional hydrogen bonds are shown as blue dashed
lines, C–HO interactions by green dashed lines. 2′ and 3′ identify
the hydroxyl groups of the nicotinamide ribose and 2, 4, 6 the C
atoms of the pyridine moiety. Leu159 is placed below the cofactor
ribose and for reasons of clarity is not labelled.
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There are ﬁve putative C-H···O hydrogen bonds, four
shown in Fig. 6. These involve the nicotinamide interact-
ing with a b-phosphate oxygen, the carbonyl groups of
Cys160 and Gly205, and side-chain of Asn93. The
remaining interaction, not shown, involves C5 and a water
molecule. These C-H···O interactions are weak (Leonard
et al., 1995) but contribute to the association of protein
with cofactor, help to align the nicotinamide to facilitate
hydride transfer from C4 and may even contribute to the
formation of the transition state during catalysis.
The cofactor binding motif of most SDR family
members, GlyX3GlyXGly, where X is any amino acid type
(Duax et al., 2003), is replaced in PTR1 by GlyX3ArgXGly,
with the arginine side-chain (Arg14 in TbPTR1, Arg17
in LmPTR1) interacting directly with the NADP+
pyrophosphate. This interaction, together with two hydro-
gen bonds donated to the carbonyl groups of Leu208 and
Leu209 (only the former is depicted in Fig. 6) forces the
main-chain to adopt an unfavourable conformation; Arg14
is the only residue that displays a generously allowed f/y
combination in the Ramachandran plot.
There is a signiﬁcant difference between TbPTR1 and
LmPTR1 with respect to nicotinamide binding by the
b6-a6 loop, which is also involved in MTX binding. In
TbPTR1, the nicotinamide N7 and O7 groups interact with
the main-chain carbonyl group of residue Leu208 and the
main-chain amide of Ser207 (Fig. 6). In LmPTR1, the
polypeptide chain at the C-terminal segment of b6 adopts
a different conformation allowing both N7 and O7 to inter-
act with the main-chain atoms of the conserved serine
(Ser227; not shown).
MTX binding
The electron density for MTX in complex with TbPTR1 is
well deﬁned over the entire molecule (Fig. 2B) in contrast
to the structures of LmPTR1 and TcPTR2, where the g-Glu
tail is poorly deﬁned (Gourley et al., 2001; Schormann
et al., 2005) and LtPTR1 where the inhibitor was not
Table 2. Potential hydrogen-bonding contacts (3.5 Å) formed by the cofactor (NADP
+) and inhibitor MTX in TbPTR1 active site A.
Cofactor atom Partner MTX atom Partner
Adenine N6 OD1 Asp62 Pteridine N1 a-Phosphate O2P
Adenine N6 Water Pteridine N2 OG Ser95
Adenine N7 Water Pteridine N2 O Ser95
Adenine N1 N Leu63 Pteridine N3 Nicotinamide O2’
Adenine O2′ Water Pteridine N4 OH Tyr174
Adenine O1P N Ser37 Pteridine N4 Water
Adenine O1P N His35 Pteridine N5 Water
Adenine O1P Water Pteridine N8 Water
Adenine O2P OG Ser37 pABA O Water
Adenine O2P Water pABA N Water
Adenine O2P
a Adenine O3’ g-Glu O1 Water
Adenine O3P N Asn36 g-Glu O2 Water
Adenine O3P Two waters g-Glu N Water
Adenine ribose O3′
a Adenine O2P g-Glu OE1 Water
Adenine ribose O3′ Two waters g-Glu OE2 Water
a-Phosphate O1P Water
a-Phosphate O2P N1 MTX pteridine
a-Phosphate O2P Two waters
b-Phosphate O1P N Ile15
b-Phosphate O1P Water
b-Phosphate O2P NH1 Arg14
b-Phosphate O2P
a Nicotinamide N7
b-Phosphate O5
ab Nicotinamide C2
Nicotinamide ribose C5
b OD1 Asn93
Nicotinamide ribose O3′ NZ Lys178
Nicotinamide ribose O3′ O Asn93
Nicotinamide ribose O3′ Water
Nicotinamide ribose O2′ NZ Lys178
Nicotinamide ribose O2′ N3 MTX pteridine
Nicotinamide C2
ab b-Phosphate O5
Nicotinamide C4
b O Gly205
Nicotinamide C5
b Water
Nicotinamide C6
b O Cys160
Nicotinamide O7 N Ser207
Nicotinamide N7 O Leu208
Nicotinamide N7
a b-Phosphate O2P
a. Intramolecular interaction.
b. C-H···O interactions.
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tion (Zhao et al., 2003).
The association between TbPTR1/NADP+ and MTX is
primarily through interactions with the pteridine moiety,
which is sandwiched between the nicotinamide and
Phe97. This phenylalanine forms a hydrophobic region at
the edge of the catalytic centre by association with
Phe171 (Fig. 5) and Tyr177 (not shown). All functional
groups of MTX participate in hydrogen-bonding interac-
tions with the enzyme and the cofactor, either directly or
via solvent-mediated hydrogen-bonding networks (Fig. 7,
Table 2). Four of the six N atoms of the pteridine moiety
make direct interactions: N1 with the a-phosphate group
of the cofactor and is likely protonated, N2 donates hydro-
gen bonds to the side-chain hydroxyl and main-chain
carbonyl groups of Ser95, N3 accepts a hydrogen bond
from the 2′ hydroxyl group of the nicotinamide ribose. The
amino N4 donates two hydrogen bonds to Tyr174 and a
water molecule. The remaining two N atoms, N5 and N8,
interact with water molecules. The former accepts a
hydrogen bond from the N4-bound water, which also
associates with the modiﬁed Cys168 and another water
that links with the side-chain of Asp161 (not shown). N8
interacts with a water molecule that in turn associates with
the cofactor a-phosphate and other waters. A noteworthy
similarity between PTR1 and DHFR is that the pteridine
moiety of MTX binds in a different orientation to that
adopted by substrates (Charlton et al., 1985; Matthews
et al., 1985; Gourley et al., 2001) with the pteridines
rotated about the N2–N5 axis by 180° relative to each
other. This difference results from each ligand adopting a
speciﬁc orientation to satisfy and maximize hydrogen-
bonding capacity.
The para-aminobenzoic acid (pABA) and g-Glu compo-
nents of MTX are directed out of the binding site with the
g-Glu tail of MTX directed towards the N-terminus of the
b6-a6 loop. Hydrogen-bonding interactions are formed
only with water molecules, two of which also interact with
functional groups on the enzyme. A well-deﬁned water
links the pABA carbonyl with NE1 of Trp221 and another
links g-Glu OE1 and OE2 to the amide of Gly214 (not
shown). The pABA moiety is positioned with Phe97 and
Phe171 on one side, Met213 and Trp221 on the other.
The methyl substituent at N10 participates in van der
Waals interactions with the side-chain of Val206 and with
a dimethylarsinoyl-modiﬁed Cys168. Cacodylate was
used as the buffer in the crystallization mixture and this
will be discussed below.
The b6-a6 loop is well deﬁned in TbPTR1 and adopts a
similar conformation in all subunits. In contrast, in
LmPTR1, this loop is ﬂexible and adopts different
conformations. In this section of PTR1 the sequence
homology between the L. major and T. brucei enzymes is
poor (Fig. 4A) and differences are observed (Fig. 8). For
example, in LmPTR1 Asp232 interacts with Arg17, which
is involved in cofactor binding. The arginine is conserved
in both structures (Arg14 in TbPTR1) but this interaction is
removed as the residue that corresponds to LmPTR1
Asp232 is TbPTR1 Pro210 (Fig. 8). The position of a6
observed in TbPTR1 places Met213 and Trp221 closer to
the pABA group compared with the corresponding resi-
Fig. 7. Hydrogen bond interactions formed by MTX with TbPTR1
and cofactor. The van der Waals surface of cacodylate modiﬁed
Cys168 is shown and coloured purple for As, green for C and red
for O. Blue numbers mark the N atoms of the MTX pteridine group.
Phe97 is not labelled.
Fig. 8. Overlay Ca trace of the b6-a6 loops and part of the helices
of TbPTR1 (black) and LmPTR1 (red). Side-chains for Lmptr1
residues are shown as red sticks. Both conformers of TbPTR1
Glu217 are shown.
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ence of the larger tryptophan side-chain at this position in
TbPTR1 compared with a histidine in LmPTR1, or tyrosine
in both TcPTR2 and LtPTR1 in conjunction with the a6
adjustment reduces the size of the pABAbinding region in
the enzyme derived from the African trypanosome and
introduces a signiﬁcant chemical change in this area of
the active site.
The quaternary structure places the C-terminal section
of one subunit close to the active site of a partner subunit.
In LmPTR1, a basic residue, Arg287 is directed towards
and linked through solvent to the catalytic centre (Gourley
et al., 2001). In TbPTR1 the C-terminal basic residue is
His267 but the presence of Trp221 in conjunction with a
chemically modiﬁed Cys168 (the corresponding residue is
Leu184 in LmPTR1) occludes the presence of a solvent
network in this part of the active site. The modiﬁcation of
Cys168 by reaction with cacodylate buffer to form dim-
ethylarsinoyl cysteine is intriguing but not unusual in
protein chemistry and it is uncertain whether such reac-
tivity has a biological function in T. brucei. The arrange-
ment of the C-terminus carboxylate, the penultimate
residue His267, and Cys168 of the partner subunit is
similar to that observed for the catalytic triad of cysteine
proteases (Tyndall et al., 2005). Such an arrangement
may enhance the reactivity of the cysteine. One other
solvent-exposed residue, Cys59, is modiﬁed to dimethy-
larsinoyl cysteine. Nearby,  5 Å distance, is His33, which
may also help to activate that thiol group. Examples of
omit difference density maps for the modiﬁcation of Cys59
and Cys168 of subunit A are shown in Fig. S1 in Supple-
mentary material.
The presence of dimethylarsinoyl in the active site, a
consequence of using cacodylate buffer, could compro-
mise kinetic characterization therefore assays were
carried out in citrate, phosphate and acetate buffers.
Mass spectrometry characterization of freshly puriﬁed
sample was consistent with an unmodiﬁed protein (data
not shown) and recently, isomorphous crystals of TbPTR1
were obtained in 10 mM sodium citrate buffer and the
high-resolution structure indicates that both Cys59 and
Cys168 are not modiﬁed (unpublished data).
Concluding remarks: the stage is set for structure-based
inhibitor design
Combinations of drugs, each displaying independent
modes of action, can improve efficacy in antimicrobial
treatments without increasing toxicity and with the added
beneﬁt of providing some protection against the develop-
ment of drug resistance. Examples of therapeutically
useful combinations include dapsone with chloroproguanil
or pyrimethamine to combat malaria (Olliaro and Taylor,
2003). The principle is well established and compatible
with a strategy that involves targeting two enzyme activi-
ties, those of DHFR and PTR1, towards the goal of devel-
oping new treatments for trypanosomatid infections. Either
asinglemoleculethatisapotentinhibitorofbothenzymes,
ortwocompoundsspeciﬁcforeacharerequired.Anumber
of compounds active against both enzymes have been
characterized but in these cases either PTR1 is less sus-
ceptible to inhibition than DHFR or the level of inhibition is
poor (Hardy et al., 1997; Schüttelkopf et al., 2005) hence
such molecules lack efficacy against trypanosomatids.
Pyrimethamine is a highly potent inhibitor of T. brucei
DHFR and would constitute a suitable drug partner to be
combined with a speciﬁc novel inhibitor of PTR1 (Jaffe
et al., 1969; Sirawaraporn et al., 1988).
Despite being able to catalyse the same reaction,
DHFR presents distinct structural features compared with
PTR1 allowing it to bind cofactor and substrate or inhibi-
tors in any order, although with a kinetic preference.
DHFR also undergoes extensive conformational changes
upon ternary complex formation (Sawaya and Kraut,
1997; Schnell et al., 2004), whereas PTR1 appears more
rigid (Schüttelkopf et al., 2005). DHFR exhibits much
stronger interactions, electrostatic and hydrophobic, with
the pABA-g-Glu group of various ligands than PTR1 while
the latter enzyme presents a sterically restricted catalytic
centre, in particular with the presence of a phenylalanine
(Phe97 in TbPTR1) that associates intimately with the
pteridine. These differences render it extremely difficult to
envisage a single compound with the necessary inhibitory
properties for use against both DHFR and PTR1.
There are already potent DHFR inhibitors with well-
characterized pharmacokinetics (Kompis et al., 2005) and
we conclude that the priority must be development of
PTR1 inhibitors to complement existing drugs.
The structural similarity of PTR1/PTR2 from different
species suggests that inhibitors are likely to have broad-
spectrum activity. However, the active site of TbPTR1
offers distinct features of interest. First, the presence of
Trp221 near the substrate binding site provides a valuable
feature to factor into inhibitor design with excellent poten-
tial to exploit the side-chain and enhance hydrophobic
interactions with inhibitors. While this opportunity could
greatly assist the development of a tight binding PTR1
inhibitor such a molecule may only be sufficiently potent
against TbPTR1. Given that the most serious need is for
the development of new treatments for African sleeping
sickness this is not a drawback. Second, the fortuitous
placement of a reactive cysteine (Cys168) near the cata-
lytic centre offers the possibility of ‘tethering’ to assist the
development of novel inhibitors (Erlanson et al., 2004). In
such an approach molecular fragments that bind via a
cysteine-linked intermediary are identiﬁed and subse-
quently embroidered in a structure-based approach to
improve inhibition.
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LmPTR1:inhibitor complexes (Schüttelkopf et al., 2005) to
design and test chemical entities in the search for novel
lead compounds. Access to an efficient TbPTR1 expres-
sion system, a reliable inhibition assay and to reproduc-
ible crystallization conditions that produce well-ordered
samples will greatly assist this structure-based approach
to inhibitor discovery.
Experimental procedures
Organisms and reagents
Trypanosoma brucei S427 (MITat1.4) was used as a source
of genomic DNA. All routine manipulations were performed in
E. coli strain XL-10 gold and overexpression in strain
BL21(DE3) (Novagen). All chemicals were sourced from
Sigma-Aldrich, BDH and CalBiochem. Restriction enzymes
and DNA-modifying enzymes were from Promega or New
England Biolabs.
PCR ampliﬁcation of a putative TbPTR1 and cloning
into pET15b
A putative sequence was identiﬁed from T. brucei Gene Data
Bank (http://www.genedb.org) Tb927.8.2210 and an EBI
mRNA sequence AF049903. Primers used to generate the
full-length open reading frame by PCR were: forward
(5′-CATATGATGGAAGCTCCCGCTGC-3′) containing an
NdeI site and start codon, and reverse (5′-
GGATCCTTAGGCATGCACAAGGCTTAAC-3′) which incor-
porated a BamHI site and stop codon. The resulting 0.8 kb
fragment was cloned (via pCR-Blunt II-TOPO vector)
into pET15b (Novagen) to generate the plasmid
pET15b_TbPTR1. Clones were sequenced and compared
with the annotated Gene Data Bank sequence and EBI
mRNA sequence.
Puriﬁcation and enzyme assay
The E. coli strain BL21(DE3) was heat-shock transformed
with pET15b-TbPTR1H, which adds a histidine tag to the
N-terminus of the protein product, and selected on Luria–
Bertani agar plates containing ampicillin (100 mg ml
-1). Bac-
teria were cultured at 37°C in SuperBroth with 100 mg ml
-1
ampicillin to mid-log phase at which point expression
of TbPTR1 was induced with 1 mM isopropyl-b-D-
thiogalactopyranoside and cell growth continued with vigor-
ous aeration overnight at 25°C. Cells were harvested by
centrifugation (3500 g, 10 min, 4°C) then resuspended in
50 mM Tris-HCl, pH 7.5, 250 mM NaCl with addition of
DNase (Sigma) at 5 mgm l
-1. The cells were lysed at a pres-
sure of 25 Kpsi (One Shot, Constant Cell Disruptions
Systems) and the extract clariﬁed by centrifugation (30 000 g,
40 min, 4°C). The supernatant was ﬁltered and applied to a
5 ml metal chelate affinity column (HiTrap; GE-Healthcare)
previously charged with Ni
2+. Unbound proteins were
removed by washing with 10 column volumes of 50 mM Tris-
HCl pH 7.5, containing 250 mM NaCl. The application of a
0–480 mM imidazole gradient in the same buffer, subse-
quently eluted His-tagged TbPTR1. Fractions containing the
protein were identiﬁed by SDS-PAGE, pooled and dialysed
overnight against 20 mM Tris-HCl pH 7.5 and the protein
concentrated to 20 mg ml
-1. The high purity of the sample
was conﬁrmed with SDS-PAGE and matrix-assisted laser
desorption/ionization time-of-ﬂight mass spectrometry and
the yield of enzyme established as approximately 25 mg l
-1
bacterial culture. Enzyme activity was ﬁrst investigated with
an established spectrophotometric assay carried out at 30°C
in 50 mM Na phosphate buffer, pH 6.0 (Bello et al., 1994).
The pH optima for substrates were determined by similar
assay. Solutions containing TbPTR1 (200 mgm l
-1) and 40 mM
substrate (biopterin, DHB, folate and DHF) were buffered
with 20 mM sodium citrate (pH 3.0–4.5), 20 mM sodium
acetate (pH 3.75–5.5) or 20 mM potassium phosphate
(pH 6.0–8.0). The reaction was initiated by addition of
100 mM NADPH and the decrease in absorbance was fol-
lowed at 340 nm.
Km values for substrates were determined in a similar
fashion except that biopterin and DHB concentrations varied
f r o m1t o8 0mM, the TbPTR1 concentration was 20 mgm l
-1
and the assay was buffered with 20 mM sodium citrate,
pH 3.7. Data were ﬁtted by non-linear regression analysis
using GraFit (http://www.erithacus.com/graﬁt/). A plot of initial
velocity (v) versus substrate concentration of DHB (S)
showed high substrate inhibition and was ﬁtted to the follow-
ing equation:
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where Vmax, Km and Ki
S are the apparent constants for the
varied substrate (S) at a ﬁxed saturating concentration of the
co-substrate NADPH (Copeland, 2000).
A dose–response curve was generated for MTX inhibition
with the addition of 0.1–10 mM MTX to the assay mixture. The
dose–response curve was also analysed with GraFit using
Morrison’s quadratic equation for tight binding inhibition
(Morrison, 1969):
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where vi and v0 are the rates with and without inhibitor, [E]T
and [I]T are the total concentrations of enzyme and inhibitor
and Ki
app is the apparent dissociation constant for the
enzyme inhibitor complex, before correction for the inhibition
modality-speciﬁc inﬂuence of substrate concentration relative
to Km. As MTX competes for binding with the pterin substrate,
Ki can be calculated according to the equation:
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where S and Km refer to the pterin substrate.
Crystallographic analysis
A ternary complex of TbPTR1 with cofactor and MTX was
prepared by incubating PTR1 (6 mg ml
-1), 1 mM NADP
+,
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pH 7.0, on ice for 20 min and crystallization screens carried
out. Hanging drops were assembled by mixing 1.5 mlo f
protein solution with 1.5 ml of reservoir and incubated over
100 ml of reservoir, 0.1 M sodium cacodylate pH 6.5 and
1.4 M sodium acetate. Well-ordered monoclinic blocks
(0.1 mm ¥ 0.1 mm ¥ 0.05 mm) grew at room temperature in
several days.
Acrystal was brieﬂy soaked in 30% glycerol and 70% of the
reservoir solution then ﬂashed cooled to -173°C in a stream
of nitrogen gas (X-stream, Rigaku-MSC). Diffraction data
were measured using a Rigaku Micromax 007 rotating anode
(CuKa, l=1.5418 Å, 40 kV, 18 mA) and R-AXIS IV
++ dual
image plate detector system. Data to 2.2 Å resolution were
collected using oscillations of 0.5° with an exposure time of
10 min per image, and processed using Denzo/Scalepack
(Otwinowski and Minor, 1997) and CCP4 (Collaborative
Computing Project Number 4, 1994) software. Five per cent
of the data were ﬂagged for the calculation of Rfree to monitor
reﬁnement protocols. The crystals display space group P21,
with unit cell dimensions a = 74.6, b = 90.2, c = 80.8 Å,
b=115.8°. A homotetramer of total mass approximately
114 kDa constitutes the asymmetric unit.
A poly Ala model for a subunit based on LmPTR1 (Gourley
et al., 2001; Protein Data Bank code 1E92) was used in
molecular replacement calculations (MOLREP; Vagin and
Teplyakov, 2000). Four copies of this model, denoted sub-
units A–D, were positioned in the TbPTR1 unit cell with the
quaternary structure typical of many SDR family members.
Following rigid body reﬁnement (REFMAC5; Murshudov et al.,
1997), the Rwork was 40.1% (Rfree 46.9%) and the correlation
coefficient was 0.56. Rounds of restrained maximum likeli-
hood reﬁnement, model manipulation and graphic inspection
of electron density (2Fo-Fc) and difference density (Fo-Fc)
maps (Fo is the observed structure-factor amplitudes, Fc the
structure-factor amplitudes calculated from the model) were
carried out using REFMAC5 and COOT (Emsley and Cowtan,
2004). The placement of ligands, water molecules and
assignment of several multiple conformers completed the
analysis. NCS restraints were not imposed on the model
during reﬁnement.
Several residues could not be modelled satisfactorily due
to diffuse electron density. This applies to the surface loops
that link b4 with a4, and a4 with b5. The residues in the ﬁrst
segment could not be identiﬁed in any of the four polypeptide
chains of the asymmetric unit, and those from the latter
segment could be modelled in subunit C only. Large positive
features observed in difference density maps in the vicinity of
Cys59 and Cys168, for all subunits, were compatible with
covalent modiﬁcation by cacodylate to form dimethylarsinoyl
cysteine. Two positive difference density peaks were also
observed between the His179 side-chains of subunits A and
C, and chains B and D. These were modelled as Ni
2+ and
assigned occupancy of one-third. The presence of cacodylate
and Ni
2+ are artefacts of the crystallization and puriﬁcation
processes respectively.
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Fig. S1. The difference density omit map (chicken wire) for
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This material is available as part of the online article from
http://www.blackwell-synergy.com
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